In the future, if approved, antagonists of the prostaglandin D2 receptors DP1 and CRTH2 and peptide YY receptor antagonists, specifically targeting the Y1 and Y2 receptors, may become important drugs in the treatment of hypertension. The gene discussed is PTGDR; the disease is hypertensive disorder.